The current study was designed to understand the systemic interaction of host factors during infection to determine whether the ERp29/Cx43 axis has the capacity to be targeted as a therapeutic approach to inhibit viral replication and its associated cellular dystrophy. This evidence concerns the gene ERP29 and infection.